Targeting Advanced Malignancies with Regional Therapies
This educational activity is designed to highlight current issues in the management of patients with peritoneal surface malignancies. Historically, malignant peritoneal mesothelioma (MPM) has been considered an aggressive and lethal neoplasm. However, contemporary series have demonstrated improved outcomes following a combination of cytoreductive surgery and intraperitoneal chemotherapy. There is evidence that suggests patient survival would improve with surgical therapy.
For example, peritoneal dissemination in colorectal cancer patients represents stage IV disease, and therefore it is usually treated with a combination of cytotoxic chemotherapy and biological agents. Currently there is growing evidence to show that just as there is a subset of patients with stage IV disease with liver metastases who have a long-term benefit from the surgical eradication of their metastatic disease, there is a subset of patients with peritoneal dissemination from colon cancer that may benefit from a complete cytoreduction and HIPEC.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
At the conclusion of this activitity, participants will be able to demonstrate:
- The current evidence behind peritoneal-based therapies
- Outcomes of patients undergoing regional therapies
- Future research directions in the field
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following:
|Kiran Turaga, MD, MPH||Castle Biosciences||Speaker|
In accordance with the ACCME® standards for Commercial Support Number 6, these relationships were reviewed via the MCW conflict of interest resolution process and resolved.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.